Lyon: Raise target price of SINO BIOPHARM (01177) to HKD 9.2, reiterate "outperform" rating

date
21/07/2025
avatar
GMT Eight
The bank believes that China Biologic Products (01177) has entered a long-term upward cycle.
Lyon released a research report stating that they believe SINO BIOPHARM (01177) has entered a long-term uptrend cycle, mainly benefiting from the continued introduction of innovative drugs from 2025 to 2027; improvement in research and development capabilities; and China's more favorable policies towards innovative drugs. Therefore, the bank has revised its net profit forecast for China Biopharmaceuticals in 2025 to 2027, with increases of 1%, decreases of 3%, and increases of 25% respectively, and has raised the target price from 7 Hong Kong dollars to 9.2 Hong Kong dollars, reiterating a "Buy" rating.